Sugammadex Injection, Solution
Product Images NDC 68462-696

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sugammadex (NDC 68462-696). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-200mg (Carton 200mg)

Packaging label for Sugammadex Injection 200 mg/2 mL (100 mg/mL) intravenous solution by Glenmark Pharmaceuticals Inc., USA. The carton indicates the product is for intravenous use only and contains 10 single-dose vials of 2 mL each. The label highlights the sterile, non-pyrogenic aqueous solution characteristics and storage instructions.*

FDA Label Image

Carton-500mg (Carton 500mg)

Packaging label for Sugammadex Injection 500 mg/5 mL (100 mg/mL) in injection, solution form for intravenous use. The label indicates the product is supplied as 10 x 5 mL single-dose vials, is Rx only, and distributed by Glenmark Pharmaceuticals Inc., USA. The label includes storage instructions and dosage notes, with branding and barcodes present.*

FDA Label Image

Label-200mg (Label 200mg)

Label for Sugammadex Injection 200 mg/2 mL (100 mg/mL) in a 2 mL single-dose vial. The product is for intravenous use only and is distributed by Glenmark Pharmaceuticals Inc., USA. The label includes storage instructions and batch information space, noting the product is made in India.*

FDA Label Image

Label-500mg (Label 500mg)

Label for Sugammadex Injection 500 mg/5 mL (100 mg/mL) single-dose vial for intravenous use only. The label includes active ingredient information, manufacturer Glenmark Pharmaceuticals Inc., USA, and storage guidelines. It is a sterile, non-pyrogenic solution in a 5 mL vial labeled for prescription use.*

FDA Label Image

Logo (Logo)

FDA Label Image

Sugammadex-spl-image-1 (Sugammadex Spl Image 1)

A line graph depicting cumulative recovery rate over time in minutes for two substances: sugammadex and neostigmine. The x-axis represents time to recovery (0 to 120 minutes), and the y-axis shows cumulative recovery rate (0 to 1.0). The graph includes median recovery times with quartiles for sugammadex (1.4 minutes) and neostigmine (21.5 minutes) from a study.*

FDA Label Image

Sugammadex-spl-image-2 (Sugammadex Spl Image 2)

A cumulative recovery rate graph comparing recovery times for sugammadex and neostigmine over 120 minutes. The y-axis shows cumulative recovery rate from 0 to 1, and the x-axis shows time to recovery in minutes. The plot includes median recovery times with quartiles for both drugs, illustrating faster recovery with sugammadex.*

FDA Label Image

Sugammadex-spl-structure-1 (Sugammadex Spl Structure 1)

Chemical structure diagram of sugammadex, showing its circular molecular arrangement with multiple sodium carboxylate groups and hydroxyls, consistent with its known complexing agent structure used in intravenous injection formulations.*

FDA Label Image

Sugammadex-spl-structure-2 (Sugammadex Spl Structure 2)

Chemical structure of sugammadex, showing its complex cyclic molecular configuration with multiple hydroxyl groups and sodium carboxylate residues.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.